AptarGroup, Inc. 10-Q Summary: Quarter Ended September 30, 2000
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2000, and the nine-month period ended on that date. AptarGroup, Inc. is a global manufacturer of dispensing systems, including pumps, valves, and closures, serving the fragrance, cosmetic, pharmaceutical, and personal care markets. The company operates significant facilities in Europe (51% of Q3 sales) and the United States (40% of Q3 sales).
Key Financial Metrics
| Metric | Q3 2000 | Q3 1999 | 9M 2000 | 9M 1999 |
|---|---|---|---|---|
| Net Sales | $224.7M | $210.5M | $670.0M | $617.6M |
| Operating Income | $28.6M | $28.9M | $88.3M | $81.5M |
| Net Income | $16.2M | $12.9M | $50.3M | $43.3M |
| Diluted EPS | $0.45 | $0.35 | $1.38 | $1.17 |
| Operating Margin | 12.7% | 13.7% | 13.2% | 13.2% |
| Net Cash from Operations (9M) | $95.2M (vs. $93.0M prior year) | |||
| Cash and Equivalents | $45.7M (as of Sept 30, 2000) | |||
| Total Debt (Short + Long Term) | $285.2M (Notes payable + Current maturities + Long-term) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7% in Q3 and 8% in the first nine months of 2000 compared to 1999. Excluding foreign currency translation and acquisitions, organic sales growth was approximately 14% for Q3 and 13% for the nine-month period.
- Profitability: Net income rose 26% in Q3 and 16% for the nine months. The Q3 1999 comparison is impacted by a one-time $3.3 million charge for in-process research and development (IPR&D) related to a 1999 acquisition, which did not recur in 2000.
- Cost Structure: Cost of sales as a percentage of net sales increased to 63.5% in Q3 2000 from 62.0% in Q3 1999, driven by price pressure and underutilization of fixed costs in the U.S. personal care and household markets.
- Geographic Mix: European operations contributed 73% of operating income in Q3 2000, up from 66% in the prior year, while U.S. contribution to operating income declined to 37% from 40%.
- Stock Repurchases: The company completed a $25.0 million repurchase of 1 million shares authorized in late 1999. Subsequent to the quarter end, the Board authorized an additional repurchase of up to 2 million shares.
Guidance, Outlook, and Risks
- Q4 2000 Outlook: Management anticipates internal sales growth (excluding currency and acquisitions) in the 0% to 5% range. Earnings per share are expected to be between $0.35 and $0.40, compared to $0.42 in the prior year.
- Market Demand: Demand for fragrance/cosmetic systems is expected to increase. Demand for pharmaceutical dispensing systems is expected to soften temporarily due to high order levels in Q4 1999. Demand in the U.S. personal care and household markets is expected to remain soft.
- Tax Rate: A German corporate tax rate reduction (from 40% to 25%) effective in 2001 is expected to reduce the full-year 2000 effective tax rate to approximately 34% and the 2001 rate to 32%-34%.
- Foreign Exchange: A stronger U.S. dollar negatively impacted reported sales. The company has significant exposure to the Euro, South American currencies, and the Chinese Renminbi.
- Liquidity: The company maintains a $75 million revolving credit agreement with $10 million available as of June 30, 2000. Capital expenditures for the full year 2000 are projected at approximately $90 million.
Investor Verification Checklist
- Verify the sustainability of the 14% organic sales growth rate given the softness in the U.S. personal care and household markets.
- Monitor the impact of the stronger U.S. dollar on future earnings translation, particularly from European operations.
- Confirm the timing and magnitude of the temporary slowdown in pharmaceutical dispensing systems demand.
- Review the execution of the new $25.0 million stock repurchase program authorized post-quarter.
- Assess the impact of the German tax law change on deferred tax liabilities and future cash flows.